Gene therapies featured prominently among this year's newsworthy drugs, some of which have already received a green light from regulatory agencies for sale or are otherwise surging forward in trials. Other drugs ended the year with a much less rosy efficacy or safety profile.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
30 December 2016
In the December 2016 issue, the piece “Drugs that made headlines in 2016 ” (Nat. Med. 22, 1377–1379, 2016) incorrectly stated that the FDA was further reviewing the drug Keytruda for a common form of lung cancer under priority review. The approval that had been given to the drug in October was the result of a priority review. The error has been corrected in the HTML and PDF versions of this article.
Rights and permissions
About this article
Cite this article
Keener, A. Drugs that made headlines in 2016. Nat Med 22, 1377–1379 (2016). https://doi.org/10.1038/nm1216-1377
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1216-1377
This article is cited by
-
Correction
Nature Medicine (2017)
